01 January 2026 | News
Image Courtesy: Public Domain
Surgerii Robotics completed a USD 100 million financing round. This round was led by Loyal Valley Capital (LVC), with continued follow-on investment from Shanghai Healthcare Capital. Additional participants included V Star Capital, DNV Capital, Hefei Industry Investment, among others. The raised funds will be primarily allocated to advancing the clinical application and market expansion of Surgerii Robotics' products across multiple surgical specialties both within China and internationally, as well as to the research and development of next-generation products. These efforts aim to further solidify Surgerii Robotics' leading position in the global single-port surgical robotics field.
Driving Global Transformation in Minimally Invasive Surgery with China's Original Technology
The core technology of the SHURUI single-port surgical robot originates from the innovative "Dual Continuum Mechanism" design by Professor Kai Xu of Shanghai Jiao Tong University. This design effectively addresses the limitations of traditional continuum mechanisms in terms of reliability and load capacity. Based on this breakthrough, the developed snake-arm single-port surgical robot can perform highly complex and precise surgical operations through a single tiny incision of only 1.8 cm.
Surgerii Robotics' global competitiveness is rooted in its fully integrated and entirely self-developed intellectual property system. During this financing round, investment institutions conducted a systematic review of Surgerii Robotics' intellectual property. This involved an in-depth analysis of the global technological and patent landscape in the surgical robotics field, including a detailed comparison of over 3,000 valid authorized patents held by major global laparoscopic surgical robotics companies in key European and American markets.
The analysis indicates that despite the highly dense patent landscape in this sector, Surgerii Robotics has achieved disruptive innovation and differentiated breakthroughs in key technologies through its proprietary "Dual Continuum Mechanism" systematic technology. This approach distinguishes it significantly from the existing international patent framework, enabling the company to successfully build its own forward-looking and multi-layered global patent portfolio. This robust foundation provides both technical and legal support for the compliant operation and commercial expansion of the SHURUI single-port surgical robot in international markets.
Advancing Clinical Applications and Global Commercial Deployment in Parallel
The SHURUI single-port surgical robot received market approval from China's National Medical Products Administration (NMPA) in June 2023, making it the first single-port laparoscopic surgical robot approved for commercialization in China. In August 2025, it obtained the EU CE certification, authorizing its use in benign and malignant surgical procedures across urology, gynecology, general surgery, and thoracic surgery for both adults and children. This milestone establishes it as the only single-port surgical robot with CE certification approved for pediatric use and the first Chinese surgical robot authorized for application across all age groups in the European Union.
To date, the SHURUI single-port surgical robot holds a market share exceeding 90% in China's single-port surgical robotics sector. Surgerii Robotics has established clinical collaborations with over 70 top-tier hospitals in China, including leading institutions such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital. The system has successfully completed more than 3,000 surgeries, pioneering nearly 50 globally innovative surgical procedures and over 80 novel techniques that represent first-time achievements in Asia and China. These milestones span highly complex cases, from pancreaticoduodenectomy for pancreatic cancer to procedures on a seven-day-old infant—the youngest patient—demonstrating the system's disruptive technological capacity to reduce trauma while extending patient eligibility beyond the scope of multi-port surgical robots. With strong support from the new round of financing, Surgerii Robotics will further explore the precise extension of its product's clinical applications, develop globally pioneering advanced energy-based instruments, and deepen the therapeutic value of single-port robotics across more surgical specialties and complex cases. Surgerii Robotics aims to build a disruptive, systematic solution centered on advanced technology to benefit a broader patient population.
In 2025, Surgerii Robotics partnered with the globally renowned surgical training center IRCAD to establish a European Clinical Center of Excellence, creating a standardized training system for surgeons worldwide. Leveraging its unique regulatory advantage as the only single-port robot with full specialty and all-age-group CE certification in the EU, Surgerii Robotics is now competing directly with international leading products in high-end markets. With the completion of this financing round, the company's global strategy will accelerate, enabling this China-originated, innovative technology to serve patients worldwide.
